You are here

Establishing a mechanistic foundation for drug discovery: The ABCA4 transporter in Stargardt Disease and other retinopathies

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41EY030401-01
Agency Tracking Number: R41EY030401
Amount: $230,686.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NEI
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-05-01
Award End Date (Contract End Date): 2020-10-31
Small Business Information
36R CARVER ST
Cambridge, MA 02138
United States
DUNS: 081277677
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JONATHAN MOORE
 (978) 758-0602
 jmm6120@mit.edu
Business Contact
 JONATHAN MOORE
Phone: (978) 758-0602
Email: moore@rectifypharma.com
Research Institution
 MASSACHUSETTS INSTITUTE OF TECHNOLOGY
 
255 MAIN STREET NE18-901
CAMBRIDGE, MA 02142-1029
United States

 Nonprofit College or University
Abstract

ABCAis an ABC transporter found in retinal photoreceptor cellsMutations in ABCAhave been implicated in retinopathies such as autosomal recessive Stargardt macular degenerationcone rod dystrophyretinitis pigmentosa and age related macular degenerationABCAfunctions as an importerandflippasemoving N retinylidene phosphatidylethanolamineN retinylidene PEfrom the lumen to the cytoplasmic leaflet of disc membranesPrevious studies indicate that mutations in ABCAprofoundly influence this flippase activityresulting in a buildup of toxic retinoid substrates in the lumenA potential approach for treatment of Stargardt Disease is to correct these functional defects with small molecule transport modulatorsThis approach is analogous to the use of small moleculepotentiatorssuch as KalydecoVertex Pharmaceuticalsto successfully correct channel gating defects in the GD CFTR mutant in Cystic FibrosisThe discovery of ABCAdirected therapeutics to treat retinal disease requires development of novel assays to measure restoration of transporter function for ABCAdisease mutantsMoreoverthese assays must be scalable to screen largee gK to andgtMsmall molecule compound librariesOur specific aims are toestablish proof ofconcept for a robust high throughput screeningHTSplatform for ABCAdirected drug discoveryFirsta biochemical platform must be developed for assessment of the functional and structural consequences of common disease variants of ABCAMammalian cell expression protocols will be established for wild type ABCAand a panel of ABCAdisease mutantsPurification and reconstitution of ABCAinto liposomes will then be optimized for functional assay developmentExisting literature lipid transport assays measure active transport of ABCAsubstratessuch as radiolabeled Nretinylidene PEor fluorescent lipidsfrom the membrane inner leaflet to the outer leafletThese assay protocols are unsuitable for high throughput screeningHTSof small molecule librariesas they rely either on a cumbersome centrifugation step to separate donor proteoliposomes from acceptor liposomesor multiple quenching steps and detergent additionwhich would introduce significant error and impose technical constraints in a high throughput settingTo address these limitationswe will use a simple phospholipid tagging strategy to allow separation of donor proteoliposomes from acceptor liposomes in a high throughput formatWe will establish protocols in which biotinylated lipids are incorporated into acceptor liposomesallowing these liposomes to be tethered to streptavidin coated substrates on multi well filter plates commonly used in HTSAfter a wash step to remove the proteoliposomesthe acceptor can then be measured by either scintillation proximity methods with a radiolabeled substrateor total fluorescence for a fluorescent phospholipid substrate Project Narrative This research describes a novel approach for identifying small molecule drugs for treatment of Stargardt Disease and related retinopathiesIf successfulthis strategy may provide a platform for discovery of new therapies for treatment of additional rare diseases caused by functional defects in ABC transporter proteins

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government